Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013

BOULDER, Colo., Jan. 29, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:   ARRY) will report financial results for the second quarter of fiscal 2013 on Monday, February 4, 2013, and will hold a conference call on Tuesday, February 5, 2013 at 9:00 a.m. eastern time to discuss these results.  Ron Squarer, Chief Executive Officer and Michael Carruthers , Chief Financial Officer will lead the call.

Conference Call Information

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company with significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.  Array-invented MEK162 will be tested in a Phase 3 trial in NRAS melanoma in the next several months as well as BRAF mutant melanoma later in 2013 (with Novartis).  Four other Array invented drugs are also approaching Phase 3 decisions by the end of calendar year 2013.  These include Array's wholly owned drugs, ARRY-614 and ARRY-520, and two additional partnered programs, selumetinib (with AstraZeneca) and danoprevir (with InterMune / Roche).  For more information on Array, please go to www.arraybiopharma.com.

SOURCE Array BioPharma Inc.

RELATED LINKS
http://www.arraybiopharma.com